Anti-Infective Vaccines Market

How big is the Anti-Infective Vaccines Market in 2026?

USD 71.9 billion in 2026, reaching USD 219.4 billion by 2036 at an 11.8% CAGR

The anti-infective vaccines market is estimated at USD 71.9 billion in 2026 and is forecast to reach USD 219.4 billion by 2036 at an 11.8% CAGR. Demand is shaped by infectious disease prevention, where inactivated vaccines protect against bacterial and viral diseases. Inactivated Vaccines account for 46.3% of Product Type demand in 2026, while bacterial Ddseases hold 58.6% of applications.

The market was valued at USD 64.3 billion in 2025. Growth reflects expanding immunization programs and rising demand for vaccines against infectious disease. Demand is shaped by hospitals and immunization programs administering inactivated and conjugate vaccines through intramuscular delivery to pediatric and adult populations.

Anti-infective vaccines prevent bacterial and viral disease across immunization programs. Buyers judge vaccines through efficacy and immunization coverage. Procurement centers on hospital and public-health immunization channels.

Metric	Value
2025 Market Size	USD 64.3 billion
2026 Market Size	USD 71.9 billion
2036 Market Size	USD 219.4 billion
Forecast CAGR (2026-2036)	11.8%
Product Type Focus	Inactivated Vaccines
Inactivated Vaccines Share (2026)	46.3%
Application Focus	Bacterial Diseases
Bacterial Diseases Share (2026)	58.6%
Key Countries	USA, Germany, France, UK

Summary of the Anti-Infective Vaccines Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Demand rests on pediatric immunization against bacterial disease, with conjugate vaccines widening protection. Immunization programs administer inactivated vaccines to pediatric populations for bacterial disease prevention. Rising infectious disease awareness drives demand for vaccines against bacterial and viral diseases. Conjugate vaccine adoption extends protection across pediatric and adult immunization.
Product and Segment View	Inactivated vaccines and bacterial-disease prevention lead the mix, delivered mainly intramuscularly. Inactivated Vaccines account for 46.3% of Product Type demand, anchored by bacterial disease prevention. Bacterial Diseases lead Application at 58.6% share as bacterial vaccine programs drive the largest use. Intramuscular delivery leads Route of Administration at 58.0% share as the standard vaccine delivery route.
Geography and Competitive Outlook	China leads growth on immunization expansion, while majors compete on efficacy and manufacturing scale. China is forecast to record 15.9% CAGR by 2036 due to immunization expansion and vaccine access. India and the UK follow at 14.7% and 12.2% CAGR as immunization programs and access expand. GSK and Sanofi compete with Merck through vaccine portfolios. Efficacy and manufacturing scale separate suppliers.
Analyst Opinion	Broad vaccine portfolios paired with scalable manufacturing and program access will lead as immunization expands across emerging markets. Manufacturers that combine broad vaccine portfolios with scalable manufacturing and immunization-program access will lead as expanding programs drive anti-infective vaccine demand across emerging markets. Adoption is increasing due to expanding immunization programs driving inactivated and conjugate vaccine demand. - Anurag Sharma, Principal Consultant at Future Market Insights

Why is the Anti-Infective Vaccines Market growing?

Rising Inactivated Vaccine and bacterial-disease demand in immunization programs

• Sustained procurement of inactivated vaccines is shaped by immunization programs preventing bacterial disease.
• China is leading the way with growth of 15.9%, driven by immunization expansion, vaccine access, and program coverage.
• The route segment is led by Intramuscular delivery at 58.0% share, supported by standard vaccine administration.

Demand is rising because immunization programs expand to prevent infectious disease, particularly in emerging markets. Adoption is increasing due to inactivated and conjugate vaccines, which protect against bacterial and viral disease, with hospitals and immunization programs administering vaccines through intramuscular delivery to pediatric and adult populations.

How is the Anti-Infective Vaccines Market segmented?

By Product Type, Application, Distribution Channel, Route Of Administration and End User

• Inactivated Vaccines are projected to lead Product Type with 46.3% share in 2026 due to bacterial disease prevention.
• Bacterial Diseases are expected to lead Application with 58.6% share in 2026 as bacterial vaccine programs drive use.
• Intramuscular delivery is forecast to lead Route Of Administration with 58.0% share as the standard route.

Why do Inactivated vaccines lead the Anti-Infective Vaccines Market?

• Inactivated Vaccines are expected to hold 46.3% share in 2026 because they provide established protection against bacterial disease.
• Their use in pediatric immunization programs anchors demand.

Bacterial Diseases hold 58.6% share, led by bacterial vaccine programs

• Bacterial Diseases form the leading application at 58.6% share, anchored by bacterial vaccine immunization.
• Viral diseases follow as viral vaccine programs extend.

Which distribution channel leads the market?

• Hospital pharmacies lead at 42.0% share as vaccine administration concentrates in hospitals.
• Retail pharmacies follow as outpatient and program immunization extends.

Which route of administration leads procurement?

• Intramuscular delivery leads at 58.0% share as the standard vaccine delivery route.
• Subcutaneous, oral, and nasal routes follow for specific vaccine types.

Which End User leads the market?

• Pediatric population leads End User at 46.0% share as childhood immunization drives the largest demand.
• Adult population and healthcare workers follow as adult immunization extends.

What drives and restrains the Anti-Infective Vaccines Market?

Driven by immunization program expansion; restrained by cold-chain logistics and manufacturing capacity

Immunization program expansion and infectious disease prevention support rapid growth while cold-chain logistics and vaccine manufacturing capacity constrain supply in lower-resource settings.

• Driver: Immunization programs administering inactivated vaccines to pediatric populations generate demand as expanding programs drive bacterial disease prevention across emerging markets.
• Restraint: Supply is constrained by vaccine cold-chain logistics and manufacturing capacity that limit immunization reach in lower-resource and high-burden settings.
• Opportunity: Conjugate vaccines and adult immunization can widen value by extending anti-infective protection beyond pediatric bacterial disease programs.

Immunization program expansion is lifting vaccine demand as programs prevent infectious disease. Inactivated vaccines anchor demand while conjugate vaccines extend protection.

The market is led by structural demand from immunization programs. Inactivated vaccines remain the leading product, while conjugate and live-attenuated vaccines serve specific protection. Constraints include cold-chain logistics, manufacturing capacity, and program funding.

Which factors support expansion in the Anti-Infective Vaccines Market?

Immunization programs and pediatric demand support market value across hospital and program channels

• Market value is supported by pediatric immunization programs before adult immunization adds demand.
• Vaccine pricing reflects efficacy and manufacturing scale before program funding affects realization.
• Immunization programs compare efficacy and supply reliability before vaccine procurement.

Which countries are growing fastest in the Anti-Infective Vaccines Market?

Country	CAGR
China	15.9%
India	14.7%
UK	12.2%
South Korea	12.0%
European Union	11.9%
USA	11.8%
Japan	11.5%

Source: Future Market Insights analysis, 2026.

How do country-level CAGRs compare in the Anti-Infective Vaccines Market?

The global Anti-Infective Vaccines Market is projected to expand at 11.8% from 2026 to 2036. The study covers more than 30 countries, and the primary markets are listed below.

• China is forecast to record 15.9% CAGR by 2036 as immunization expansion and vaccine access accelerate.
• India is expected to expand at 14.7% CAGR through 2036 as immunization programs and access grow.
• The UK is estimated to grow at 12.2% CAGR by 2036 as immunization programs expand.
• South Korea is projected to rise at 12.0% CAGR through 2036 as vaccine access widens.
• The European Union, USA, and Japan round out the study at 11.5% to 11.9% CAGR through 2036.

Who are the leading companies in the Anti-Infective Vaccines Market?

GSK, Sanofi, Merck, Pfizer, and Moderna

GSK and Sanofi compete through broad vaccine portfolios across bacterial and viral disease. Manufacturing scale remains a further point of differentiation. Merck and Pfizer compete on conjugate and inactivated vaccines, while Moderna holds positions in vaccine technology. These overlap with broader immunization and infectious disease buying paths.

Buyers compare manufacturers on efficacy, manufacturing scale, and program access. Immunization programs standardize on vaccines with established efficacy and reliable supply. Health systems favor manufacturers offering broad vaccine portfolios with scalable manufacturing for program coverage.

Who are the key players in the Anti-Infective Vaccines Market?

Key global companies leading the Anti-Infective Vaccines Market include:

• GSK, Sanofi, and Merck maintain leading positions through vaccine portfolios, manufacturing scale, and immunization-program relationships across global markets.
• Vaccine manufacturers such as Pfizer, Moderna, and Novavax compete through inactivated, conjugate, and platform vaccines.
• Regional and emerging manufacturers extend vaccine supply to immunization programs in high-burden markets to establish positions and scale.

How do top Anti-Infective Vaccines Market companies compare?

GSK and Sanofi lead on scale; Merck also has a global footprint, while Pfizer and Moderna are more platform-concentrated.

Company	Portfolio Breadth	Vaccine Efficacy	Manufacturing Scale	Geographic Footprint
GSK	High	High	Strong	Global
Sanofi	High	High	Strong	Global
Merck	High	High	Strong	Global
Pfizer	Moderate	High	Strong	Global
Moderna	Moderate	High	Strong	Global

Source: Future Market Insights competitive analysis, 2026.

Key Developments in the Anti-Infective Vaccines Market

• In February 2025, the FDA approved GSK's Penmenvy, a pentavalent meningococcal vaccine covering serogroups A, B, C, W and Y, for individuals aged 10 through 25 years, with ACIP voting to recommend its inclusion in the adolescent immunisation schedule. Five-in-one coverage reduces the number of injections required for broad meningococcal protection. Simplified scheduling evidence supports immunisation programme managers assessing whether consolidation can lift adolescent meningococcal coverage rates before the next school-year cycle. 

• In March 2026, the FDA expanded approval of GSK's Arexvy RSV vaccine to include high-risk adults aged 18 to 49 years, based on phase 3b data demonstrating non-inferior immunogenicity relative to adults aged 60 and older. Age-indication expansion opens RSV vaccination to a younger at-risk population previously ineligible. Broader eligibility evidence supports health systems evaluating whether adult RSV procurement volumes need revision before the next respiratory season. 

• In June 2025, the FDA expanded approval of Moderna's mResvia mRNA RSV vaccine to include adults aged 18 to 59 years at increased risk of RSV-associated lower respiratory tract infection. A second RSV vaccine entering the younger-adult segment intensifies competition and widens payer access. Parallel expansion evidence supports formulary committees comparing mRNA and adjuvanted RSV platforms before selecting preferred products for at-risk populations. 

Key Players in the Anti-Infective Vaccines Market

Global Vaccine Leaders

• GlaxoSmithKline (GSK)
• Sanofi
• Merck & Co.

Platform Vaccine Manufacturers

• Pfizer Inc.
• Moderna Inc.

Emerging Vaccine Players

• Novavax Inc.

Anti-Infective Vaccines Market - Scope & Definition

Attribute	Detail
Market Definition	Anti-infective vaccines including inactivated, conjugate, and live-attenuated vaccines used to prevent bacterial and viral disease across immunization programs
Functions Covered	Infectious disease prevention, immunization, and protection across bacterial and viral diseases
Applications Covered	Bacterial diseases, viral diseases, and other infectious disease prevention
End-Use Industries	Pediatric population, adult population, healthcare workers, and military personnel
Inclusions	Inactivated, conjugate, and live-attenuated vaccines across intramuscular, subcutaneous, oral, and nasal routes
Exclusions	Therapeutic vaccines outside infectious disease prevention, and non-vaccine immunotherapies

Anti-Infective Vaccines Market - Research Methodology

Method	Description
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing & Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

What does the Anti-Infective Vaccines Market report cover?

2021 to 2025 history and 2026 to 2036 forecasts across all segments and 30+ countries

Parameter	Details
Forecast period	2026 to 2036
Historical period	2021 to 2025
Quantitative unit	Value in USD billion
By Product type	Inactivated Vaccines, Conjugate Vaccines, Live-Attenuated Vaccines, Others
By Application	Bacterial Diseases, Viral Diseases, Others
By Distribution channel	Hospital Pharmacies, Retail Pharmacies, Others
By Route of Administration	Intramuscular (IM), Subcutaneous (SC), Oral, Nasal
By End user	Pediatric Population, Adult Population, Healthcare Workers, Military Personnel
Regions covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries covered	USA, China, India, UK, South Korea, European Union, Japan, and other major markets
Key companies profiled	GSK, Sanofi, Merck, Pfizer, Moderna, Novavax
Approach	Bottom-up immunization-based approach using program volume, vaccine-type mix, application, and supplier disclosures

Market Segmentation Analysis

Anti-Infective Vaccines Market Segmented by Product Type:

• Inactivated Vaccines
  • Killed Pathogen Vaccines
    • Broad Immunity Response
    • Stable Storage Formulation
  • Split Virion Vaccines
    • Purified Antigen Response
    • Reduced Side Effects
• Conjugate Vaccines
  • Polysaccharide Conjugates
    • Enhanced Immune Response
    • Pediatric Immunization
  • Protein Conjugates
    • Improved Antigen Recognition
    • Long Term Protection
• Live - Attenuated Vaccines
  • Weakened Pathogen Vaccines
    • Strong Immune Response
    • Long Lasting Immunity
  • Recombinant Live Vaccines
    • Genetically Modified Strains
    • Targeted Protection
• Others
  • Subunit Vaccines
    • Purified Antigen Based
    • Lower Risk Profile
  • DNA And mRNA Vaccines
    • Next Generation Platforms
    • Rapid Development

Anti-Infective Vaccines Market Segmented by Application:

• Bacterial Diseases
  • Pneumococcal Infections
    • Pneumonia Prevention
    • Meningitis Protection
  • Meningococcal Diseases
    • Serogroup Targeted Vaccines
    • Outbreak Control
  • Diphtheria And Tetanus
    • Routine Immunization
    • Combination Vaccines
• Viral Diseases
  • Influenza
    • Seasonal Vaccination Programs
    • Pandemic Preparedness
  • Hepatitis (A & B)
    • Liver Infection Prevention
    • Chronic Disease Reduction
  • Measles Mumps Rubella (MMR)
    • Childhood Immunization
    • Highly Contagious Disease Control
• Others
  • Parasitic Infections
    • Emerging Vaccine Targets
    • Travel Related Diseases
  • Regional Infectious Diseases
    • Localized Immunization Programs

Anti-Infective Vaccines Market Segmented by Distribution Channel:

• Hospital Pharmacies
  • Inpatient Vaccination Centers
    • Emergency Immunization
    • Post Exposure Treatment
  • Outpatient Departments
    • Routine Vaccination Programs
• Retail Pharmacies
  • Community Pharmacies
    • Accessible Vaccination Points
    • Public Health Distribution
  • Chain Pharmacies
    • Mass Immunization Support
    • Convenient Access Points
• Others
  • Government Health Programs
    • National Immunization Drives
    • Public Vaccine Distribution
  • NGO And International Agencies
    • Global Vaccination Campaigns
    • Rural Healthcare Support

Anti-Infective Vaccines Market Segmented by Route Of Administration:

• Intramuscular (IM)
  • Vaccine Injection in Muscle
    • Most Common Delivery Method
    • Strong Systemic Immune Response
• Subcutaneous (SC)
  • Vaccine Injection Under Skin
    • Controlled Antigen Release
    • Lower Pain Administration
• Oral
  • Oral Vaccine Formulations
    • Easy Mass Immunization
    • No Needle Requirement
• Nasal
  • Intranasal Vaccines
    • Mucosal Immunity Activation
    • Needle Free Delivery

Anti-Infective Vaccines Market Segmented by End User:

• Pediatric Population
  • Infants And Children
    • Routine Immunization Programs
    • School Vaccination Drives
• Adult Population
  • Young Adults
    • Preventive Immunization
    • Occupational Vaccination
  • Elderly Population
    • High Risk Disease Protection
    • Booster Dose Administration
• Healthcare Workers
  • Hospital Staff
    • Exposure Risk Protection
    • Mandatory Immunization Programs
• Military Personnel
  • Defense Forces
    • Biological Threat Protection
    • Mandatory Vaccination Programs

Anti-Infective Vaccines Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Türkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• World Health Organization. (2025, October). Global immunization coverage and vaccine report.
• Organisation for Economic Co-operation and Development. (2025, November). Health at a Glance: immunization rates.
• USA Food and Drug Administration. (2026, February 10). Approved anti-infective vaccines.
• European Medicines Agency. (2025, December 9). Vaccine assessment reports.
• Gavi, the Vaccine Alliance. (2025, September). Global immunization program coverage data.
• GlaxoSmithKline (GSK). (2026, February 4). 2025 annual report and vaccines portfolio overview.
• Sanofi. (2026, January 30). 2025 results and vaccines franchise update.

This bibliography is provided for reader reference and is not exhaustive.

This Report Answers

• Market size estimates for 2026 and forecasts through 2036 for the Anti-Infective Vaccines Market.
• Analysis of product-type demand across inactivated and conjugate vaccines.
• Country-level growth analysis covering China and India with UK, South Korea, European Union and additional country outlooks.
• Evaluation of company positioning across GSK and Sanofi with Merck, Pfizer and Moderna.
• Assessment of drivers and restraints with immunization patterns across hospital and program channels.